Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.

@article{Bacon2012TripleTW,
  title={Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.},
  author={Bruce R. Bacon and Omer Khalid},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2012},
  volume={32 Suppl 1},
  pages={51-3}
}
This is an excellent time for patients with hepatitis C virus infection who have failed past treatment with standard of care (SOC) peginterferon (PEG-IFN) and ribavirin (RBV). New treatments have been shown to increase sustained virological response (SVR) rates. Previous relapsers and those with some responsiveness to interferon will clearly benefit from protease inhibitor-based therapy. Patients with little interferon response may not be suited for these regimens, but can be treated by careful… CONTINUE READING